Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

GlobeNewswire November 7, 2023

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire November 7, 2023

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 6, 2023

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

GlobeNewswire November 2, 2023

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

GlobeNewswire October 24, 2023

ADC Therapeutics to Participate in September Investor Conferences

GlobeNewswire September 5, 2023

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

GlobeNewswire August 30, 2023

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 8, 2023

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

GlobeNewswire August 1, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

PR Newswire July 25, 2023

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

GlobeNewswire July 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Newsfile July 23, 2023

ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

GlobeNewswire July 20, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

PR Newswire July 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

PR Newswire July 13, 2023

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

GlobeNewswire July 11, 2023

ADC Therapeutics Announces Evolution of Board of Directors

GlobeNewswire June 15, 2023

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

GlobeNewswire June 9, 2023

ADC Therapeutics to Participate in the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

Business Wire May 11, 2023